Dr. Milind Deshpande, President and CEO of Achillion.

The Connecticut Sino-American Pharmaceutical Professionals Association (SAPA-CT) has successfully organized the 2nd Annual Conference on March 22, 2015 at Yale University. With more than 200 attendees, this year’s conference highlights the cooperation between U.S. and China’s biopharmaceuticals, emphasizing the rising opportunities beyond the manageable challenges.

Leaders from U.S. and China biopharmaceuticals provided insights to innovation at multiple levels. The plenary session was opened with Dr. John Houston, Senior Vice President, Disease Sciences & Biologics, Bristol-Myers Squibb Company. Dr. Houston attributed the company’s huge success in immuno-oncology field to the focused strategy with the innovation at the core. Followed by was a talk given by Dr. Milind Deshpande, President and CEO of Achillion, where innovation and global cooperation was seminal to the company’s recent success in the treatment of Hepatitis C virus. Further example of innovation came from Nature’s Fingerprint. Dr. John Jasper disclosed their unique approach to protect biopharmaceutical process patent through ambient distribution of light stable isotypes.

SAPA-CT has set up the mission to serve the biopharmaceutical community by reaching out the local biopharma companies as well as non-profit organizations like CURE. This was best interpreted when Dr. Susan Froshauer, President and CEO of CURE, stepped on the stage. Citing herself in the career context and her passion for CURE as example, Dr. Froshauer encouraged scientists to participate actively in the pharmaceutical community and explained how this service can help to build a portal between CT and China bioscience. Dr. Peter Farina, Co-chair and board member of CURE, also shared his experience in developing a successful career in corporate environment. Dr. Yongmei Li, 2015-2016 President of SAPA-CT, commented on the SAPA-CURE relationship as “productive and mutually beneficial”. Leaders from both sides agree to further collaborations in scientific exchange and business promotion at the individual, organization, and governmental levels.

Biopharmaceuticals are experiencing dynamic changes in many aspects. Among those, markets, regulations, and talents must be leveraged to achieve sustainable growth in next decades. Everett Hoekstra, Senior Vice President, Boehringer Ingelheim Pharma, Inc, first discussed the conflict between healthcare innovation and value-based healthcare and how to find a common starting point for them to thrive together. Dr. Shoufeng Li, CEO of Aucta Pharmaceuticals, LLC, shared his experience in operating a start-up company and how he managed to orchestrate resources from U.S. and China to make Aucta successful. It’s well received that global cooperation will transform the unprecedented opportunities into a win-win situation.

To learn more about the event, visit